130 related articles for article (PubMed ID: 7483501)
1. Ultracentrifugal analysis of factor VIII and von Willebrand factor in therapeutic preparations.
Aronson DL; Chang P
Vox Sang; 1995; 69(1):8-13. PubMed ID: 7483501
[TBL] [Abstract][Full Text] [Related]
2. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.
Weiss HJ; Sussman II; Hoyer LW
J Clin Invest; 1977 Aug; 60(2):390-404. PubMed ID: 17621
[TBL] [Abstract][Full Text] [Related]
3. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.
Brinkhous KM; Sandberg H; Garris JB; Mattsson C; Palm M; Griggs T; Read MS
Proc Natl Acad Sci U S A; 1985 Dec; 82(24):8752-6. PubMed ID: 3936044
[TBL] [Abstract][Full Text] [Related]
4. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of factor VIII-von Willebrand factor association.
Vlot AJ; Koppelman SJ; Meijers JC; Dama C; van den Berg HM; Bouma BN; Sixma JJ; Willems GM
Blood; 1996 Mar; 87(5):1809-16. PubMed ID: 8634427
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease.
Morfini M; Mannucci PM; Tenconi PM; Longo G; Mazzucconi MG; Rodeghiero F; Ciavarella N; De Rosa V; Arter A
Thromb Haemost; 1993 Aug; 70(2):270-2. PubMed ID: 8236134
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the von Willebrand factor/factor VIII complex produced by a novel purification process.
Ahn JW; Chang ES; Jung YJ; Kim SR; Seong BL; Ha SH
Arch Pharm Res; 2020 Jul; 43(7):714-723. PubMed ID: 32666302
[TBL] [Abstract][Full Text] [Related]
8. Assessment of multimeric structure and ristocetin-induced binding to platelets of von Willebrand factor present in cryoprecipitate and different factor VIII concentrates.
López-Fernández MF; López-Berges C; Corral M; García-Talavera JR; López Borrasca A; Batlle J
Vox Sang; 1987; 52(1-2):15-9. PubMed ID: 3111088
[TBL] [Abstract][Full Text] [Related]
9. Biochemical properties of Monoclate factor VIII:C antihemophilic factor (human) using monoclonal antibody to von Willebrand factor (VWF).
Nilsson IM
Semin Hematol; 1988 Apr; 25(2 Suppl 1):33-7. PubMed ID: 3133776
[No Abstract] [Full Text] [Related]
10. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor.
Vlot AJ; Koppelman SJ; van den Berg MH; Bouma BN; Sixma JJ
Blood; 1995 Jun; 85(11):3150-7. PubMed ID: 7756647
[TBL] [Abstract][Full Text] [Related]
11. Identification of aggregates in therapeutic formulations of recombinant full-length factor VIII products by sedimentation velocity analytical ultracentrifugation.
Healey JF; Parker ET; Lollar P
J Thromb Haemost; 2018 Feb; 16(2):303-315. PubMed ID: 29197156
[TBL] [Abstract][Full Text] [Related]
12. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
13. [Properties of factor VIII/von Willebrand factor in two highly-purified factor VIII concentrates, Hemofil M and Monoclate, using monoclonal antibodies].
Tanaka I; Yoshioka A; Shima M; Fujiwara T; Terada S; Nakai H; Miyata S; Sawamoto Y; Kamisue S; Fukui H
Rinsho Ketsueki; 1989 Jul; 30(7):951-7. PubMed ID: 2509762
[TBL] [Abstract][Full Text] [Related]
14. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
Deitcher SR; Tuller J; Johnson JA
Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
[TBL] [Abstract][Full Text] [Related]
15. In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency).
Giles AR; Tinlin S; Hoogendoorn H; Fournel MA; Ng P; Pancham N
Blood; 1988 Jul; 72(1):335-9. PubMed ID: 3134068
[TBL] [Abstract][Full Text] [Related]
16. Studies on the nature of antihemophilic factor (factor VIII). Further evidence relating the AHF-like antigens in normal and hemophilic plasmas.
Bennett B; Forman WB; Ratnoff OD
J Clin Invest; 1973 Sep; 52(9):2191-7. PubMed ID: 4199413
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
18. The pro-polypeptide of von Willebrand factor is required for the formation of a functional factor VIII-binding site on mature von Willebrand factor.
Leyte A; Voorberg J; Van Schijndel HB; Duim B; Pannekoek H; Van Mourik JA
Biochem J; 1991 Feb; 274 ( Pt 1)(Pt 1):257-61. PubMed ID: 1900418
[TBL] [Abstract][Full Text] [Related]
19. The role of fibronectin in factor VIII/von Willebrand factor cryoprecipitation.
Mazurier C; Samor B; Deromeuf C; Goudemand M
Thromb Res; 1985 Mar; 37(6):651-8. PubMed ID: 3922084
[TBL] [Abstract][Full Text] [Related]
20. A new method measuring the interaction between von Willebrand factor and coagulation factor VIII.
Karlman M; Holmström M; Wiman B
Thromb Res; 2011 Jan; 127(1):47-50. PubMed ID: 21094987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
